A Houston company has acquired a data analytics business. Photo via Getty Images

Houston-based KBR announced it has entered into a definitive agreement to acquire engineering, data analytics and digital integration company LinQuest Corp., which will add “digital integration capabilities for national security customers” according to a news release. The deal is valued at $737 million.

LinQuest is known for assisting in solving complex technical challenges for national security missions and has supported the U.S. Space Force, U.S. Air Force and other U.S. Department of Defense and intelligence agencies. The company does this through development and integrating advanced technology solutions across space, air dominance and connected battle space missions. Some missions include advanced AI and machine learning capabilities.

KBR is a leader in providing science, engineering and technology solutions to governments and companies worldwide.

“LinQuest is an innovator in national security, space and technology solutions. Their talented people deliver high-end, technically and digitally differentiated services that are complementary to KBR,” Stuart Bradie, KBR president and CEO said in a news release.

KBR’s support for strategic U.S. government clients in terms of the rapidly changing defense and national security sector expect to benefit from the fact that over 74 percent of LinQuest’s 1,500-plus employees already hold security clearances.

“LinQuest is a terrific company, and the revenue synergy opportunities are exciting,” Bradie adds. ”Our values are strongly aligned, and we are delighted to welcome this talented team to the KBR family.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”